Literature DB >> 25657304

Managing bipolar II disorder: some personal perspectives.

Gordon Parker1.   

Abstract

OBJECTIVE: The aim is to overview a personal model for managing bipolar II disorder.
METHOD: The model describes the author's personal approach and observes the relative lack of an evidence base.
RESULTS: Key 'macro' and treatment component approaches are overviewed.
CONCLUSIONS: It is suggested that bipolar II disorder is categorically distinct from bipolar I, in lacking any psychotic features during contrasting mood states and thus allowing that its management should not necessarily extrapolate strategies used to manage bipolar I disorder. If valid, in addition to there being less of a need to prescribe antipsychotic drugs, the differing mood stabilizers may have quite differing gradients of efficacy across the bipolar I and II disorders. © The Royal Australian and New Zealand College of Psychiatrists 2015.

Entities:  

Keywords:  bipolar II disorder; bipolar disorders; management

Mesh:

Substances:

Year:  2015        PMID: 25657304     DOI: 10.1177/1039856214568219

Source DB:  PubMed          Journal:  Australas Psychiatry        ISSN: 1039-8562            Impact factor:   1.369


  3 in total

1.  Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective study.

Authors:  Jay D Amsterdam; Lorenzo Lorenzo-Luaces; Irene Soeller; Susan Qing Li; Jun J Mao; Robert J DeRubeis
Journal:  J Affect Disord       Date:  2015-06-26       Impact factor: 4.839

2.  Comparison of treatment outcome using two definitions of rapid cycling in subjects with bipolar II disorder.

Authors:  Jay D Amsterdam; Lorenzo Lorenzo-Luaces; Robert J DeRubeis
Journal:  Bipolar Disord       Date:  2017-02-03       Impact factor: 6.744

3.  Improving treatment decision-making in bipolar II disorder: a phase II randomised controlled trial of an online patient decision-aid.

Authors:  Alana Fisher; Rachael Keast; Daniel Costa; Louise Sharpe; Vijaya Manicavasagar; Josephine Anderson; Ilona Juraskova
Journal:  BMC Psychiatry       Date:  2020-09-17       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.